Vinorelbine ditartrate for injection (NVB) is a new monobasic vinblastine sulfate drug developed by Pierre Fabre. The molecule target is the dynamic balance of microtubule protein / microtubule. It can combine with microtubule protein so as to form an obstacle in karyo-genetic division process and induce microtubule to disaggregate so as to stop the division growth of tumor cells at mitosis metaphase, and then generates its anti-tumor effects.

It is shown in the Extra-organ anti-tumor researches that vinorelbine has fairly strong effect to human body tumor cell line such as lung cancer (small cell or non-small cell), breast cancer, leukemia, colon carcinoma and so on.

The main applicable symptoms of vinorelbine are in the following: non-small cell lung cancer, metastatic breast cancer, malignant lymphoma and late state ovarian cancer.

The Vinorelbine ditartrate for injection produced by Shenzhen Main Luck Pharmaceuticals Inc. is a kind of national basic medicines and the secondary national essential medical insurance drugs. It is trustable for the excellent quality.